The abuse of prescription and illegal opioids, such as morphine and heroin, is a major problem in the U.S., with devastating public health, economic and social consequences. That's why scientists are searching for new medicines to help break the cycle of addiction. Now, researchers reporting in ACS' Journal of Medicinal Chemistry have re-engineered the structure of vincamine, a plant-derived compound, so that it reduces morphine-seeking behaviors in mice.
According to the U.S. Centers for Disease Control and Prevention, more than 130 people died each day from an opioid overdose in 2017. To develop a drug to treat opioid addiction, Robert Huigens III, and colleagues wondered if they could use a natural product as a starting point to synthesize new compounds. Many plant-produced compounds have complex structures that can bind to therapeutically relevant biological targets. Huigens reasoned that by altering the structure of one such compound, vincamine -- an indole alkaloid from the leaves of the plant Vinca minor -- they might obtain a molecule that binds to new protein targets involved in opioid addiction, thereby blocking the drugs' "high" sensations.
The team altered vincamine's chemical structure, producing a diverse library of 80 small molecules. They then screened seven of these molecules for the ability to bind to certain protein receptors and block their action. One of the molecules, which they refer to as "V2a," inhibited a protein called hypocretin receptor 2 (HCRTR2) that is involved in heroin dependence, whereas the parent compound, vincamine, had no effect. The researchers then tested this compound in mice, finding that pretreatment with V2a prevented mice from spending extra time in a chamber where morphine is administered. In another experiment, mice that had "recovered" from morphine addiction, and then were treated with V2a, did not relapse to morphine-seeking behaviors in response to stress, unlike mice that were not treated with the new molecule. The team also conducted molecular modeling experiments to visualize how the compound binds to HCRTR2, which could allow them to tweak the structure of the compound for even stronger binding and efficacy.
The authors acknowledge funding from the University of Florida, the American Cancer Society, the National Institutes of Health, the Debbie and Sylvia DeSantis Chair in Natural Products Drug Discovery and Development and the National Science Foundation.
The abstract that accompanies this study is available here.
For more research news, journalists and public information officers are encouraged to apply for complimentary press registration for the ACS Spring 2020 National Meeting & Exposition in Philadelphia.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact firstname.lastname@example.org.